Crohn's Disease 2020: Pipeline Review - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Crohn's Disease (Regional Enteritis) - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Crohn's Disease - Pipeline Review, H1 2020, provides an overview of the Crohn's Disease (Gastrointestinal) pipeline landscape.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Crohn's Disease - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Crohn's Disease (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Crohn's Disease (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Crohn's Disease (Regional Enteritis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 15, 36, 30, 1, 70, 19 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 3 and 2 molecules, respectively.

Crohn's Disease (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Crohn's Disease (Gastrointestinal).
• The pipeline guide reviews pipeline therapeutics for Crohn's Disease (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Crohn's Disease (Gastrointestinal) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Crohn's Disease (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Crohn's Disease (Gastrointestinal)

Reasons to buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Crohn's Disease (Gastrointestinal).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Crohn's Disease (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

• Introduction
• Crohn's Disease (Regional Enteritis) - Overview
• Crohn's Disease (Regional Enteritis) - Therapeutics Development
• Crohn's Disease (Regional Enteritis) - Therapeutics Assessment
• Crohn's Disease (Regional Enteritis) - Companies Involved in Therapeutics Development
• Crohn's Disease (Regional Enteritis) - Drug Profiles
• Crohn's Disease (Regional Enteritis) - Dormant Projects
• Crohn's Disease (Regional Enteritis) - Discontinued Products
• Crohn's Disease (Regional Enteritis) - Product Development Milestones
• Appendix

Companies Mentioned

• 4D Pharma Plc
• AbbVie Inc
• Abivax SA
• Aclaris Therapeutics Inc
• Active Biotech AB
• Affilogic SAS
• Aibios Co Ltd
• Akeso Biopharma Inc
• AlfaSigma SpA
• Algernon Pharmaceuticals Inc
• Allergan Plc
• Alpha Cancer Technologies Inc
• Alvotech ehf
• Amgen Inc
• Anterogen Co Ltd
• Antibe Therapeutics Inc
• Arena Pharmaceuticals Inc
• Artelo Biosciences Inc
• Artizan Biosciences Inc
• Asdera LLC
• Atlantic Bio Sci LLC
• Atlantic Healthcare Plc
• Avexegen Therapeutics Inc
• Avobis Bio
• Axim Biotechnologies Inc
• Baylx Inc
• BioLingus AG
• Biond Biologics Ltd
• BioXpress Therapeutics SA
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Co
• Celltrion Inc
• Celularity Inc
• ChemoCentryx Inc
• Chong Kun Dang Pharmaceutical Corp
• Commence Bio Inc
• Cytocom Inc
• Daiichi Sankyo Co Ltd
• DBV Technologies SA
• Defensin Therapeutics ApS
• Denali Therapeutics Inc
• DM Bio Ltd
• DNX Biopharmaceuticals Inc
• EA Pharma Co Ltd
• Eisai Co Ltd
• Eli Lilly and Co
• Enterome Bioscience SA
• Enzo Biochem Inc
• ETX Pharma Inc
• ExCellThera Inc
• Exeliom Biosciences SAS
• Ferring International Center SA
• Fimbrion Therapeutics Inc
• Finch Therapeutics Group
• Fujifilm Kyowa Kirin Biologics Co Ltd
• FYB202 GmbH & Co KG
• Galactica Biotech Ltd
• Galapagos NV
• Genentech Inc
• GlaxoSmithKline Plc
• Gossamer Bio Inc
• HAV Vaccines Ltd
• Immunic Inc
• Inception Sciences Inc
• InDex Pharmaceuticals Holding AB
• InflammatoRx inc
• Innovate Biopharmaceuticals Inc
• Innovation Pharmaceuticals Inc
• Innovent Biologics Inc
• Innovimmune Biotherapeutics Inc
• InSight Biopharmaceuticals Ltd
• Inspyr Therapeutics Inc
• Intract Pharma Ltd
• JHL Biotech Inc
• Jiangsu Hengrui Medicine Co Ltd
• Johnson & Johnson
• Jyant Technologies Inc
• Kang Stem Biotech Co Ltd
• Koutif Therapeutics LLC
• Kyowa Kirin Co Ltd
• Landos Biopharma Inc
• Locus Biosciences Inc
• Machavert Pharmaceuticals LLC
• Macrophage Therapeutics Inc
• MAKScientific LLC
• Menemsha Pharmaceuticals Ltd
• Mesoblast Ltd
• Metacrine Inc
• MetiMedi Pharmaceuticals Co Ltd
• MGC Pharmaceuticals Ltd
• Mitsubishi Tanabe Pharma Corp
• Morphic Holding Inc
• Mycenax Biotech Inc
• Naia Rare Diseases Inc
• NeuClone Pty Ltd
• Nichi-Iko Pharmaceutical Co Ltd
• Nimbus Therapeutics LLC
• Oncodesign SA
• OSE Immunotherapeutics
• Otsuka Holdings Co Ltd
• PanTheryx Inc
• Par'Immune SAS
• Paradigm Biopharmaceuticals Ltd
• Pfizer Inc
• Pharmapraxis
• Polpharma Biologics
• Praeventix LLC
• Protagonist Therapeutics Inc
• Protheragen Inc
• Qu Biologics Inc
• Re-Pharm Ltd
• Rebiotix Inc
• RedHill Biopharma Ltd
• Redx Pharma Plc
• Regentys Corp
• Reponex Pharmaceuticals Aps
• Saje Pharma LLC
• Saniona AB
• Semorex Technologies Ltd
• Seres Therapeutics Inc
• Siam Bioscience Co Ltd
• Soligenix Inc
• STERO Biotechs Ltd
• Suzhou Connect Biopharmaceuticals Ltd
• Synedgen Inc
• Synlogic Inc
• TaiwanJ Pharmaceuticals Co Ltd
• Takeda Pharmaceutical Co Ltd
• Temisis Therapeutics
• Tetherex Pharmaceuticals Corp
• The Cell Factory BVBA
• Theravance Biopharma Inc
• Thetis Pharmaceuticals LLC
• Tiziana Life Sciences Plc
• TRACT Therapeutics Inc
• Trio Medicines Ltd
• Ventria Bioscience
• VHsquared Ltd
• Winston Pharmaceuticals Inc
• XBiotech Inc
• Xbrane Biopharma AB
• Yom Chai

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/w2nffd